Adrian R. Krainer sold $1.1M of STOK
director at Stoke Therapeutics, Inc.. 40,472 shares at an average of $26.98, traded Nov 14, 2025, filed Nov 18, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 10% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001780081-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 14, 2025 | SOpen-market sale Common Stock10b5-1 | -19,790 | $26.61 | $527k | 384,928 | Nov 18, 2025 |
| Nov 14, 2025 | SOpen-market sale Common Stock10b5-1 | -20,682 | $27.34 | $565k | 364,246 | Nov 18, 2025 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 34Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $313k 9,293 shares | -32% | |
| 49Moderate | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $286k 8,895 shares | -24% | |
| 50Moderate | Stoke Therapeutics, Inc. | Jason Hoitt Chief Patient Officer | $119k 3,712 shares | -27% | |
| 58Moderate | Stoke Therapeutics, Inc. | Thomas Leggett Chief Financial Officer | $147k 4,578 shares | -31% | |
| 15Weak | Stoke Therapeutics, Inc. | Arthur A Levin director | $22k 605 shares | -12% | |
| 40Moderate | Stoke Therapeutics, Inc. | Adrian R. Krainer director | $1.3M 33,243 shares | -11% | |
| 17Weak | Stoke Therapeutics, Inc. | Adrian R. Krainer director | $287k 7,229 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.